Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. by LeGoff, Jérôme et al.
Legoff, J; Mayaud, P; Gresenguet, G; Weiss, HA; Nzambi, K; Frost,
E; Pepin, J; Belec, L; the ANRS 12-12 Study Group (2008) Perfor-
mance of HerpeSelect(R) and Kalon(R) Assays to Detect Antibodies
to Herpes Simplex Virus Type 2. Journal of clinical microbiology, 46
(6). pp. 1914-8. ISSN 0095-1137
Downloaded from: http://researchonline.lshtm.ac.uk/7814/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
  Published Ahead of Print 2 April 2008. 
10.1128/JCM.02332-07. 
2008, 46(6):1914. DOI:J. Clin. Microbiol. 
Laurent Belec
A. Weiss, Khonde Nzambi, Eric Frost, Jacques Pepin and 
Jérôme LeGoff, Philippe Mayaud, Gérard Gresenguet, Helen
 
Herpes Simplex Virus Type 2
Assays in Detection of Antibodies to 
Performance of HerpeSelect and Kalon
http://jcm.asm.org/content/46/6/1914
Updated information and services can be found at: 
These include:
REFERENCES
http://jcm.asm.org/content/46/6/1914#ref-list-1at: 
This article cites 16 articles, 11 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 N
ovem
ber 21, 2013 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
 o
n
 N
ovem
ber 21, 2013 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 1914–1918 Vol. 46, No. 6
0095-1137/08/$08.000 doi:10.1128/JCM.02332-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Performance of HerpeSelect and Kalon Assays in Detection of
Antibodies to Herpes Simplex Virus Type 2
Je´roˆme LeGoff,1,2* Philippe Mayaud,3 Ge´rard Gresenguet,4 Helen A. Weiss,3 Khonde Nzambi,5
Eric Frost,6 Jacques Pepin,6 Laurent Belec,1 and the ANRS 12-12 Study Group†
Universite´ Paris Descartes, Equipe Immunite´ et Biothe´rapie Muqueuse, Unite´ INSERM Internationale U743 (Immunologie Humaine),
Centres de Recherches Biome´dicales des Cordeliers and Laboratoire de Virologie, Hoˆpital Europe´en Georges Pompidou, Paris,
France1; Laboratoire de Microbiologie, Hoˆpital Saint-Louis, Paris, France2; Clinical Research Unit, Department of Infectious and
Tropical Diseases, and Infectious Diseases Epidemiology Unit, Department of Epidemiology and Population Health, London School of
Hygiene and Tropical Medicine, London, United Kingdom3; Centre National de Re´fe´rence des Maladies Sexuellement Transmissibles et
du SIDA de Bangui and Unite´ de Recherches et d’Intervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculte´ des
Sciences de la Sante´, Bangui, Central African Republic4; West African Project To Combat AIDS and STDs, Accra,
Ghana5; and Centre for International Health, University of Sherbrooke, Sherbrooke, Canada6
Received 4 December 2007/Returned for modification 25 January 2008/Accepted 21 March 2008
The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes sim-
plex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus
(HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2
ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434
women were tested with the HerpeSelect assay, and a subsample (n 199) was tested by the Kalon assay. Ulcer
swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with
detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A
total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital
(lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index
values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the
two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had
high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection,
71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were
identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day
14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional
seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low
index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to
nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical
history.
Identification of individuals infected with herpes simplex
virus type 2 (HSV-2) is critical for the management of genital
herpes as well as for epidemiological studies and clinical trials.
The performances of commercially available assays to detect
HSV-2-specific glycoprotein G2 (gG2) antibodies vary signifi-
cantly between study populations (2). For example, the FDA-
approved and widely available HerpeSelect enzyme-linked im-
munosorbent assay (ELISA) (Focus Technologies) has a high
sensitivity and specificity, ranging from 96 to 100%, against the
reference HSV-2 Western blot (WB) assay for testing of sera
from North American or Western European populations but
significantly lower specificity for testing of sera from adult
African populations (2, 7, 16). Moreover, concordance be-
tween WB and HerpeSelect assays was found to vary between
countries in sub-Saharan Africa (2, 6, 7, 9) and according to
human immunodeficiency virus (HIV) serostatus (16). Herpe-
Select and other assays were compared in an evaluation study
using African sera from population-based surveys, and the
Kalon gG2-specific ELISA (Kalon Biologicals) was found to be
as sensitive as and more specific than HerpeSelect, with WB as
the reference method (16). Similar results were documented
for Brazilian populations, using clinicovirological reference
groups (13). To increase the specificity of HerpeSelect, some
authors have suggested using a higher index value of 3.5 for the
seropositivity cutoff instead of the manufacturer’s recom-
mended cutoff of 1.1 (2, 9, 13, 16).
A critical element in evaluating the performance of these assays
is the stage of HSV-2 infection. One study reported that the
sensitivity of HerpeSelect increased for patients suffering from
genital ulcer disease (GUD) compared to that for blood donors
(6), perhaps because HerpeSelect may detect primary genital
herpes earlier than the Kalon assay or even WB does (1, 12).
In the present report, we assess the performance character-
istics of the HerpeSelect and Kalon assays for African patients
presenting with symptomatic and molecularly documented
genital HSV-2 infection.
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MATERIALS AND METHODS
Women presenting with GUD at study sites in Ghana and the Central African
Republic were enrolled in a randomized placebo-controlled trial of acyclovir
(400 mg three times daily for 5 days) given in addition to routine syndromic
antibacterial GUD treatment (11) (ClinicalTrials register no. NCT00158483).
Briefly, eligible and consenting women with clinically verified GUD (including
blisters and sores) were interviewed and examined genitally, and samples were
obtained and tested as follows. Two swabs from the ulcer base were used to
determine GUD etiology and to detect lesional HIV type 1 (HIV-1) RNA, using
molecular methods (5, 8, 11, 14); a cervicovaginal lavage (CVL) sample was
collected to detect and quantify HSV-2 DNA and HIV-1 RNA in genital secre-
tions, using real-time PCR (10); and blood samples were obtained for detection
of HSV-2 antibodies (HerpeSelect; Focus Technologies, Cypress Hill, CA) and
HIV-1 antibodies and for CD4 lymphocyte counts, as previously described (11).
Serum samples obtained at days 14 and 28 from women who were HSV-2
seronegative at day 0 but positive for lesional and/or cervicovaginal HSV-2 DNA
(i.e., with genital HSV-2 infection) were tested using HerpeSelect to detect
possible HSV-2 seroconversion, and their enrollment (day 0) samples were
tested for HSV-1 antibodies by HerpeSelect gG1 assay (Focus Technologies) to
determine if these were cases of primary genital herpes (dually HSV-1- and
HSV-2-seronegative samples) or nonprimary first-episode HSV-2 infection
(HSV-1-seropositive and HSV-2-seronegative samples). All samples from a
given woman were tested in the same ELISA run.
The Kalon gG2-specific assay (Kalon Biologicals, Aldershot, United Kingdom)
was used to test all available sera with HerpeSelect index values ranging from
1.1 to 3.5 (n  63 of 66 sera), a random selection of 88 sera with index values
of 3.5, and 48 sera with index values of 0.9, including all cases (n  25) of
potential HSV-2 seroconverters (as defined above).
We calculated the percentage agreement between the two tests and their
concordance by Cohen’s kappa coefficient (), and we tested for differences in
positive test results by using McNemar’s 2 test for paired samples. Chi-square
tests were used to compare proportions for unpaired tests, the Wilcoxon rank
sum test was used for comparison of medians, and Spearman’s rank test was used
for correlation of categorical variables.
RESULTS
Of 441 women with GUD enrolled in the trial, 434 had
HSV-2 serological results (278 and 156 women from Ghana
and the Central African Republic, respectively). HSV-2 sero-
prevalence was higher in the Central African Republic than in
Ghana (95% versus 71%; P  0.001). Among the 413 patients
with genital samples, HSV-2 DNA was detected in 225 (54%)
by PCR with the lesional (n  208) or the CVL (n  17)
specimen (with 146 patients being positive for both samples).
Table 1 shows the distribution of HerpeSelect index values
by genital HSV-2 DNA status, combining results from the two
countries since no difference in the distributions of Herpe-
Select index values was observed (not shown). Serum samples
from 346 (80%) women were found to be HSV-2 seropositive
by HerpeSelect (index values of 1.1), of which 66 (19%) had
low-positive index values (3.5). Samples from another six
women were found to be equivocal (index values of 0.9 to 1.1),
with one being associated with positive detection of HSV-2
DNA (in the lesional sample). Overall, 58% (36/62 patients) of
women with low-positive HerpeSelect index values and 60%
(164/275 patients) of women with high-positive HerpeSelect
index values had molecular evidence of genital HSV-2 infec-
tion (P  0.8). Of the 200 HSV-2-seropositive women with
genital HSV-2 DNA, 36 (18%) had index values of 3.5.
Among HSV-2-seropositive women, there was little difference
in median index values between women with (median  6.8;
interquartile range, 4.4 to 10.2) and without (median  7.8;
interquartile range, 4.4 to 10.1) detectable genital HSV-2 DNA
(P  0.50). The frequency of recent clinical episodes was
significantly correlated with the HerpeSelect titer. An episode
of GUD in the preceding 12 months was reported by 14%,
17%, 26%, and 40% of patients in the groups with negative,
equivocal, low-positive, and high-positive HerpeSelect serol-
ogy, respectively (Spearman’s rank correlation; P  0.0001)
(Table 1).
Table 2 shows results obtained by serological testing using
both the HerpeSelect and Kalon assays, including those for
samples from patients with suspected first episodes of genital
HSV-2. Overall agreement between the two serological assays
was 86% (171/199 samples) or 87% (173/199 samples), de-
TABLE 1. Distribution of HerpeSelect gG2 index values according to genital HSV-2 DNA detection in women with GUD in Ghana and the
Central African Republic
Clinical characteristic
No. (%) of patients in HerpeSelect index value group
0.9 (negative)
(n  82)
0.9–1.1 (equivocal)
(n  6)
1.1–3.5 (low positive)
(n  66)
3.5 (high positive)
(n  280) Total (n  434)
Genital HSV-2 DNAa
Negative 49 (67) 2 (67) 26 (43) 111 (41) 188 (46)
Positive 24 (33) 1 (33) 36 (58) 164 (60) 225 (54)
History of GUD in preceding 12 mo 11 (14)b 1 (17) 17 (26) 111 (40)b 140 (32)b
a Defined as the presence of lesional and/or cervicovaginal HSV-2 DNA by real-time PCR. PCR results were undetermined for 9, 3, 4, and 5 patients in the groups
with HerpeSelect index values of 0.9, 0.9 to 1.1, 1.1 to 3.5, and 3.5, respectively, i.e., for 21 patients in total.
b PCR results were undetermined for one sample in each group, i.e., for two patients in total.
TABLE 2. Results of HerpeSelect and Kalon testing according to
assay index values
Kalon index value group
No. (%) of women in HerpeSelect index
value groupa
3.5 1.1–3.5 0.9
1.1b 87 (99) 36 (57) 0
HSV-2 DNA positive 51 25 0
HSV-2 DNA negative 36 10 0
0.9–1.1 0 2 (3) 0
HSV-2 DNA positive 0 1 0
HSV-2 DNA negative 0 1 0
0.9c 1 (1) 25 (40) 48 (100)
HSV-2 DNA positive 1 8 22
HSV-2 DNA negative 0 14 25
Total (n  199) 88 63 48
a Sera with HerpeSelect values of 0.9 to 1.1 (equivocal) were excluded from
this analysis.
b HSV DNA data are missing for one sample from the group with HerpeSelect
values of 1.1 to 3.5.
c HSV DNA data are missing for three samples from the group with Herpe-
Select values of 1.1 to 3.5 and for one sample from the group with HerpeSelect
values of 0.9.
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pending on the classification of equivocal results of the Kalon
assay as negative or positive, respectively, and concordance
defined by the kappa coefficient was good (  0.68). All 48
samples found to be negative with HerpeSelect were negative
with the Kalon assay. Similarly, all but 1 of the 88 samples with
HerpeSelect index values of 3.5 were positive with the Kalon
assay. The one discordant sample had a high HerpeSelect
index value (6.8), with HSV-2 DNA detection in both lesional
and cervicovaginal samples. The combined results of negative
samples (index values of 0.9 with both assays) and high-
positive samples (index values of 3.5 for HerpeSelect) gave
an agreement of 99% (135/136 samples), corresponding to a
high kappa coefficient (  0.98).
Among the 63 samples with HerpeSelect index values rang-
ing from 1.1 to 3.5, Kalon assay results were found to be
negative for 25 (40%) (of which 8 were associated with detec-
tion of genital HSV-2 DNA), equivocal for 2 (3%) (with 1
being positive for HSV-2 DNA in the CVL sample only), and
positive for 36 (57%).
Assuming detection of genital HSV-2 DNA (n  34) and/or
concordant seropositivity with the Kalon assay (n  36) as
confirmation of HSV-2 infection, 71% (45/63 samples) of sam-
ples with HerpeSelect index values between 1.1 and 3.5
should be considered true HSV-2 infections and would have
been misclassified using the higher cutoff of 3.5 suggested by
Hogrefe et al. (7) and Nascimento et al. (13). Among discor-
dant samples tested for HSV-2 DNA, 40% (10/25 samples)
were associated with positive detection of HSV-2 DNA (Table
2). Finally, among women found to be seropositive with Herpe-
Select and to have concomitant genital HSV-2 DNA, only 88%
(76/86 patients) were considered HSV-2 seropositive with the
Kalon assay.
Among the 76 women classified as HSV-2 seronegative or
equivocal by HerpeSelect at day 0 who had genital samples, 25
(6% of all women in the trial) had genital HSV-2 DNA de-
tected by PCR (Table 1). These patients presented to the
clinics after a median of 6 days (range, 3 to 18 days) following
symptom onset. All of these women were HSV-1 seropositive
by HerpeSelect gG1 assay and thus were classified as having
nonprimary first episodes of genital HSV-2 infection. All day 0
sera were also found to be negative by Kalon assay. Among
these women, 15 were tested on either day 14 or day 28 (10
were tested on both days, 3 were tested only on day 14, and 2
were tested only on day 28), and 11 cases of HSV-2 serocon-
version were detected, with 10 detected by HerpeSelect and 7
detected by Kalon assay. HSV-2 seroconversion was detected
earlier with HerpeSelect than with the Kalon assay (Fig. 1). At
day 14, 77% (10/13 samples) of sera were positive with Herpe-
Select, compared with only 23% (3/13 sera) with the Kalon
assay (P  0.01). Four additional seroconversions were ob-
served with the Kalon assay at day 28, and none were detected
by HerpeSelect. The median HerpeSelect index value for these
10 seroconversion cases was 4.3 (range, 2.1 to 15.9) at day 14
and 8.6 (range, 1.5 to 16.6) at day 28. Among patients with
nonprimary first episodes of genital HSV-2 infection, four were
HIV seropositive at baseline and one woman seroconverted to
HIV seropositive within 28 days. All three HIV-seropositive
samples which were tested at day 28 showed HSV-2 serocon-
version.
Forty-seven percent (202/432 women) of women included in
this study were HIV-1 seropositive. The analysis of HSV-2
serological results according to HIV-1 serostatus did not show
any effect of HIV-1 infection on the performance of Herpe-
Select. Samples giving discordant HSV-2 assay results were less
frequently HIV-1 seropositive than were those giving concor-
dant results (14% versus 48%; McNemar’s P  0.01). The
median HerpeSelect index values were similar for HIV-1-
seropositive and -seronegative samples (7.2 versus 7.5; P 
0.46).
DISCUSSION
To our knowledge, this is the first report of an evaluation of
HSV-2 seroassays among cases of genital herpes documented
through molecular methods, including cases of nonprimary
first episodes of genital HSV-2 infection in Africa. Previous
studies have suggested that the specificity of the HerpeSelect
assay for detecting HSV-2 serum antibodies may be lower for
African sera or sera from HIV-1-seropositive patients (2, 7,
16). A higher positivity cutoff index value of 3.5 (instead of the
manufacturer’s recommended cutoff of 1.1) has therefore been
suggested as a way to increase assay specificity. However, the
clinical stage of HSV-2 infection had not been ascertained in
these studies, which may have interfered with the correct in-
terpretation of results. In the present study, we aimed to re-
evaluate the significance of low HerpeSelect index values
among African patients presenting with GUD. We compared
the results obtained with HerpeSelect with those of the Kalon
serological assay, which is known to have a high specificity
(13, 16).
Our results show 99% concordance between the Herpe-
Select and Kalon assays for negative or high-positive (3.5)
HerpeSelect results, which confirms previous reports of excel-
lent agreement between these two assays (13, 16). In contrast,
the concordance was moderate when HerpeSelect positivity
included index values between 1.1 and 3.5. However, we
found that 40% (10/25 samples) of discordant samples were
associated with detection of genital HSV-2 DNA, and 71% of
samples with low-positive HerpeSelect index values could be
classified as having established HSV-2 infection when results
of molecular testing or seroconcordance were included. Over-
all, nearly 20% of the study population with positive Herpe-
FIG. 1. Number of cases and timing of HSV-2 seroconversion by
HSV-2 serological assay among 15 patients with first episodes of gen-
ital HSV-2 infection in Ghana and the Central African Republic. On
day 14, 13 women were tested. For day 28, the number of seroconver-
sion cases corresponds to the cumulative number of seroconverters on
days 14 and 28. Results of HerpeSelect are presented in black bars, and
results of the Kalon assay are shown with gray bars.
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Select serology had index values comprising between 1.1 and
3.5, 58% of whom had evidence of genital HSV-2 infection.
This is consistent with data published by Ashley-Morrow et al.
showing that 22% of U.S. patients with established HSV-2
infection had low HerpeSelect index values (3). Reciprocally,
18% of women testing positive by HerpeSelect and carrying
genital HSV-2 DNA had low HerpeSelect index values. These
findings demonstrate that a nonnegligible proportion of true
genital herpes cases would be missed by using a higher cutoff
for HerpeSelect.
The analysis of the kinetics of HSV-2 antibodies in sera
associated with nonprimary first clinical episodes of HSV-2
infection showed that HerpeSelect detected HSV-2 serocon-
version more frequently and earlier than did the Kalon assay
and that HerpeSelect index values increased rapidly. These
results corroborate data from the work of Ashley-Morrow et
al. (3) demonstrating that for newly infected patients, Herpe-
Select index values start low, often in the negative range, and
peak a median of 9 to 10 weeks later. Our results also confirm
the higher sensitivity of HerpeSelect than that of the Kalon
assay in detecting nonprimary first HSV-2 episodes, as previ-
ously reported (12). In a U.S. study including 14 patients with
nonprimary first episodes with culture-positive HSV-2 lesions,
the sensitivity of HerpeSelect was 77%, in contrast to 43% for
the Kalon assay, and the median time for seroconversion was
significantly longer by Kalon assay (149 days) than by Herpe-
Select (22 days) (12). In our study, patients with nonprimary
first episodes of HSV-2 infection presented to the clinics after
a median of 6 days (range, 3 to 18 days) following symptom
onset, and thus the maximum follow-up time to assess sero-
conversion was 46 days postonset, which explains the higher
detection rate obtained with HerpeSelect. We also found that
HerpeSelect seropositivity and index values correlated with
reported GUD symptoms in the preceding year. These results
suggest that frequent viral reactivations may sustain specific
humoral responses and, conversely, that low titers may be
related to insufficient antigenic stimulation secondary to infre-
quent viral replication, as suggested by Ashley-Morrow et al. (3).
Thus, the ability of methods to detect early HSV-2 infection
may account for some of the assay discrepancies found in our
and other studies. It is even possible that some recent HSV-2
infections may have been accompanied by a lack of HSV-2
DNA detection, since the delay between the onset of symp-
toms and presentation at the clinic for study enrollment was
quite long for some women, allowing some patients to have
already cleared the virus. Such misclassifications would have
contributed to underestimating the true sensitivity of Herpe-
Select.
We did not use the reference WB HSV assay in this study to
help resolve some of the assays’ discrepancies. However, it has
been shown that although it is highly sensitive and specific, WB
may have less ability to detect recent cases of genital herpes, as
detection of seroconversion among first episodes of genital
HSV-2 infection was slower than that of HerpeSelect (1).
Moreover, it has been shown that some discordant results
between HerpeSelect and WB on African sera were eventually
classified as true positive results by HerpeSelect after testing
with an inhibition assay (7).
Finally, our data did not support a differential performance
of HerpeSelect according to HIV serostatus. On the contrary,
we observed less discrepancy between the HerpeSelect and
Kalon assays for samples from HIV-infected women. This may
be related to the higher rate of HSV-2 reactivation in such
patients, which might sustain index values of HSV-2-specific
antibodies in the high range.
Our results confirm that some low-positive HerpeSelect in-
dex values correspond to true HSV-2 infection and that some
may be related to recent infection. Depending on population
composition, this would affect the evaluation of the perfor-
mance of the various HSV-2 serological assays, and this has to
be taken into consideration in the interpretation of study find-
ings. Moreover, the choice of HSV-2 serological assays needs
to be dictated by circumstances, whether for an epidemiolog-
ical study examining risk factors for HSV-2 or a clinical trial
seeking to enroll HSV-2-seropositive patients, for which highly
specific assays would be more desirable, or for the diagnosis
and management of patients with possible early HSV-2 infec-
tion, for which a sensitive assay would be required. Our results
have particular resonance for the management of GUD in
countries where HSV-2 infection is highly prevalent and where
clinical or subclinical primary infection may occur frequently.
The use of a sensitive assay comparable to HerpeSelect may
help to detect recent herpesvirus infection and offer appropri-
ate advice on management and counseling about the risk of
HIV acquisition, which could increase in the presence of re-
cent HSV-2 infection (4, 15).
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